drugset / Trial / NCT00686413

Positron Emission Tomography Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects

NCT00686413

Phase 1 Completed 9 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study is being performed in order to learn more about AZD3480 (potential as treatment for patients with Alzheimer's Disease) and to investigate how much of AZD3480 is bound to the nicotinic receptors in the brain at different concentrations of AZD3480 in blood, as well as to investigate the period of time for this binding.

Timeline

Start
2008-01
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ispronicline Small molecule Oral

Indications

No indication recorded.